Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8699804 | 1.00 | MAOA (0.49) | MAOAMAOBDRD2DRD1DRD4 | |
| Hydrochloric Acid SCHEMBL28232988 | 0.98 | MAOA (0.47) | MAOAMAOBDRD2DRD1DRD4 | |
| Formaldehyde SCHEMBL27689991 | 0.94 | MAOA (0.49) | MAOAMAOBDRD2DRD1DRD4 | |
| SCHEMBL281673 | 0.88 | MAOA (0.56) | MAOAMAOBDRD2DRD1DRD4 | |
| SCHEMBL27619324 | 0.85 | HSD17B1 (0.45) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL29674920 | 0.84 | CTNNB1 (0.49) | MAOAMAOBCYP3A4ESR2ESR1 | |
| SCHEMBL459693 | 0.84 | CTNNB1 (0.49) | MAOAMAOBCYP3A4ESR2ESR1 | |
| SCHEMBL28874219 | 0.82 | CTNNB1 (0.48) | MAOAMAOBCYP3A4ESR2ESR1 | |
| Ethoxycarbonyl Group SCHEMBL27889131 | 0.81 | CTNNB1 (0.41) | MAOAMAOBDRD2DRD1DRD4 | |
| SCHEMBL23259146 | 0.78 | CTNNB1 (0.40) | MAOAMAOBCTNNB1WNT3APRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-3947365-B1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-11-12 | — | — | US | disclosed |
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-09-17 | — | — | US | disclosed |
| EP-3853216-B1 | 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS | BIONOMICS LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023241598-A1 | AROMATIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PREPARATION OF ESTROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-12-21 | — | — | WO | disclosed |
| CN-116139125-A | Combination therapy | 梅制药公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116113414-A | Combination therapy | 梅制药公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MEI PHARMA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230114408-A1 | METHODS OF MODULATING T-CELL ACTIVATION USING ESTROGEN RECEPTOR BETA (ERB) AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-13 | — | — | US | disclosed |
| CN-115003295-A | Novel chroman derivatives having estrogen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | MAOA 3059/4885MAOB 2774/4885DRD2 3656/4885 |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | GABRE, GRIN2C, GRIN2A | MAOA 423/4885MAOB 453/4885DRD2 152/4885 |
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | MAOA 4290/4885MAOB 3981/4885DRD2 4804/4885 |
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | GABRE, GAP43, GRIN2A | MAOA 698/4885MAOB 659/4885DRD2 263/4885 |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | SCN3A, KCND3, GRIN3A | MAOA 1326/4885MAOB 2112/4885DRD2 501/4885 |
| US-20230114408-A1 | METHODS OF MODULATING T-CELL ACTIVATION USING ESTROGEN RECEPTOR BETA (ERB) AGONISTS | ESRRG, ESR2, ESRRB | MAOA 2749/4885MAOB 2478/4885DRD2 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.